Display options
Share it on

Int J Bipolar Disord. 2017 Dec;5(1):24. doi: 10.1186/s40345-017-0093-5. Epub 2017 Jul 09.

Long-term response to mood stabilizer treatment and its clinical correlates in patients with bipolar disorders: a retrospective observational study.

International journal of bipolar disorders

Sung Woo Ahn, Ji Hyun Baek, So-Yung Yang, Yongkang Kim, Youngah Cho, Yujin Choi, Kounseok Lee, Taesung Park, Kyung Sue Hong

Affiliations

  1. Department of Psychiatry, Sunkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  2. Department of Statistics, Seoul National University, Seoul, Republic of Korea.
  3. Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  4. Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Republic of Korea.
  5. Department of Psychiatry, St. Andrew's Hospital, Icheon-si, Republic of Korea.
  6. Department of Psychiatry, Sunkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea. [email protected].

PMID: 28480482 PMCID: PMC5502006 DOI: 10.1186/s40345-017-0093-5

Abstract

BACKGROUND: The efficacy and utility of long-term prophylactic treatment in patients with bipolar disorders (BDs) have not been fully explored. This study aims to estimate the long-term clinical response of patients with BDs to mood stabilizer treatment and to identify the clinical factors associated with that response.

METHODS: The study subjects consisted of 80 patients with bipolar I or bipolar II disorder who had been receiving treatment with lithium and/or valproate for more than 2 years at a single bipolar disorder clinic. The long-term response to the best treatment option based on treatment algorithms was evaluated using the Alda scale. Clinical characteristics were evaluated on a lifetime basis. Patients were classified into two response groups based on frequentist mixture analysis using the total Alda scale score.

RESULTS: Thirty-four percent of the patients were good responders, with a total Alda score of 5 or higher. The treatment response rate did not differ between the lithium and valproate groups, but lithium and valproate combination therapy was associated with poorer response. The number of previous mixed episodes was associated with a worse response (p = 0.026). Of individual symptoms, delusions during manic episodes (p = 0.008) and increased appetite (p = 0.035) during depressive episodes were more common in moderate/poor responders than in good responders. Co-morbid anxiety disorders were more frequently observed in the moderate/poor response group (p = 0.008).

CONCLUSIONS: Psychotic, mixed, and atypical features of BDs were found to be correlated with long-term treatment outcomes. Lithium and valproate showed similar efficacy but moderate/poor responders preferred to use polypharmacy.

Keywords: Alda scale; Bipolar disorders; Lithium; Treatment response; Valproate

References

  1. Bipolar Disord. 2013 Feb;15(1):1-44 - PubMed
  2. Br J Psychiatry. 1991 Jul;159:123-9 - PubMed
  3. PLoS One. 2013 Jun 19;8(6):e65636 - PubMed
  4. Psychiatry Res. 1997 Dec 5;73(3):159-71 - PubMed
  5. Biol Psychiatry. 2000 Jun 15;47(12):1034-42 - PubMed
  6. Bipolar Disord. 2010 Jun;12(4):390-6 - PubMed
  7. Eur Psychiatry. 2009 Apr;24(3):171-7 - PubMed
  8. J Affect Disord. 2010 Feb;121(1-2):116-26 - PubMed
  9. Neuropsychiatr Dis Treat. 2015 Jun 26;11:1561-71 - PubMed
  10. N Engl J Med. 2014 Jan 9;370(2):119-28 - PubMed
  11. Behav Sleep Med. 2016;14(2):155-68 - PubMed
  12. J Clin Psychiatry. 2010 Sep;71(9):1176-86; quiz 1252-3 - PubMed
  13. Pharmacogenomics. 2011 Nov;12(11):1559-69 - PubMed
  14. J Affect Disord. 2013 Feb 20;145(2):187-9 - PubMed
  15. Arch Gen Psychiatry. 2003 Aug;60(8):817-26 - PubMed
  16. J Affect Disord. 1993 Sep;29(1):49-52 - PubMed
  17. Psychiatr Serv. 2006 May;57(5):660-5 - PubMed
  18. Am J Psychiatry. 2004 Aug;161(8):1447-54 - PubMed
  19. ACS Chem Neurosci. 2014 Jun 18;5(6):413-21 - PubMed
  20. Bipolar Disord. 2005 Oct;7(5):404-17 - PubMed
  21. Acta Psychiatr Scand. 1977 Jan;55(1):32-40 - PubMed
  22. Int Clin Psychopharmacol. 2016 Jul;31(4):218-23 - PubMed
  23. J Affect Disord. 2007 Dec;104(1-3):185-90 - PubMed
  24. J Clin Psychopharmacol. 2014 Oct;34(5):577-87 - PubMed
  25. Neuropsychobiology. 1998;37(3):146-9 - PubMed
  26. Pharmacopsychiatry. 1985 Sep;18(5):309-13 - PubMed
  27. Am J Psychiatry. 1973 Sep;130(9):1011-3 - PubMed
  28. PLoS One. 2015 Sep 29;10(9):e0139413 - PubMed
  29. Compr Psychiatry. 2004 May-Jun;45(3):225-9 - PubMed
  30. J Affect Disord. 2006 Jul;93(1-3):13-7 - PubMed
  31. Lancet. 2016 Mar 12;387(10023):1085-1093 - PubMed
  32. J Affect Disord. 2011 Jun;131(1-3):59-67 - PubMed
  33. J Psychopharmacol. 2009 Jun;23(4):346-88 - PubMed
  34. Bipolar Disord. 2003 Apr;5(2):110-4 - PubMed
  35. Asia Pac Psychiatry. 2013 Dec;5(4):301-8 - PubMed
  36. J Clin Psychiatry. 2002 Oct;63(10):942-7 - PubMed

Publication Types